Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- CheckyesterdayChange DetectedRevision tag updated from v3.3.3 to v3.3.4; no substantive changes to study details, eligibility criteria, or contact information observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed from the footer.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedThe notice about a lapse in government funding warning that information may not be up to date was removed from the page. Core study details, contacts, and eligibility criteria remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedThe two screenshots depict the same study detail page with only minor visual and layout differences; no substantive updates to the study data (eligibility, enrollment, or outcomes) were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check101 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference4%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.